Overview Technical Risk & rank Quality Results Accounts Filings Guidance & governance
Guidance tracker
What WOCKPHARMA guided, and what came next
| Filed | What the filing says | Next results: profit YoY | Revenue | Move on the day |
|---|---|---|---|---|
| 11 Jun 2026 | Wockhardt Limited filed the transcript of its investor conference/call held on 4 June 2026, with a link to the transcript on its website. Management said Zaynich has received US FDA approval (first Indian-discovered new drug approved by the US FDA, per the filing) and will be launched in the US and India in the... NSE copy | - | +25.9 % | -1.1 % |
| 11 Jun 2025 | Wockhardt filed the transcript of its investor presentation held on 5 June 2025 (Regulation 30 disclosure), also to be posted on the company website. Dr. Murtaza Khorakiwala (Managing Director) said FY25 turnover was INR 3,033 crore, EBITDA about INR 418 crore, and EBITDA grew 67% with margin expanding from 9% to... NSE copy | - | -0.1 % | -0.6 % |
| 05 Jun 2025 | Wockhardt Limited filed its Investor Presentation (June 2025) under Regulation 30, for an investor meeting on 5 June 2025; the deck is also posted on the company website. FY25 income of INR 3,033 Cr and FY25 EBITDA of INR 418 Cr, with EBITDA growth noted year-on-year. Net Debt to Equity ratio of 0.01 as at 31 March... NSE copy | - | -0.1 % | -0.6 % |
Filings tagged as guidance, newest first (3 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.
Governance
Management, auditors, ratings and legal matters
| Filed | Kind | What the filing says |
|---|---|---|
| 11 Jun 2026 | Legal or regulatory | Wockhardt Limited filed the transcript of its investor conference/call held on 4 June 2026, with a link to the transcript on its website. Management said Zaynich has received US FDA approval (first Indian-discovered new drug approved by the US FDA, per the filing) and will be launched in the US and India in the... NSE copy |
| 21 May 2026 | Credit rating | ICRA Limited has upgraded Wockhardt Limited's credit ratings, as disclosed in the filing dated 21 May 2026. Long-term Fund Based Term Loan A- (Stable), previously BBB (Positive). Long-term/short-term Fund Based and Non Fund Based facilities and Unallocated Limits rated A- (Stable)/A2+, previously BBB... NSE copy |
| 04 May 2026 | Auditor | Board of Wockhardt Limited met on 4 May 2026 (from 11:00 a.m. to 3:10 p.m.) and approved the audited standalone and consolidated financial results for the quarter and financial year ended 31 March 2026, with the Statutory Auditor's report from M/s MSKC & Associates LLP. The Board also approved an enabling proposal... NSE copy |
| 04 May 2026 | Auditor | Board of Wockhardt Limited met on 4 May 2026 (11:00 a.m. to 3:10 p.m.) and approved the audited standalone and consolidated financial results for the quarter and financial year ended 31 March 2026, along with the statutory auditor's report from MSKC & Associates LLP and a declaration on unmodified audit opinion.... NSE copy |
| 03 Nov 2025 | Management change | Board of Wockhardt Limited approved the un-audited standalone and consolidated financial results for the quarter and half year ended 30 September 2025, with an auditor's limited review report from MSKC & Associates LLP dated 3 November 2025. The Board appointed Mr. Om Prakash Bhatt (DIN: 00548091) as Additional... NSE copy |
| 26 Aug 2025 | Credit rating | Wockhardt Limited informed BSE and NSE that ICRA Limited has upgraded its credit ratings and revised the outlook from Stable to Positive. Long-term fund-based term loan rated BBB (Positive), previously BBB- (Stable). Long-term/short-term fund-based, non-fund-based and unallocated limits rated BBB (Positive)/A3+,... NSE copy |
| 11 Jun 2025 | Legal or regulatory | Wockhardt filed the transcript of its investor presentation held on 5 June 2025 (Regulation 30 disclosure), also to be posted on the company website. Dr. Murtaza Khorakiwala (Managing Director) said FY25 turnover was INR 3,033 crore, EBITDA about INR 418 crore, and EBITDA grew 67% with margin expanding from 9% to... NSE copy |
| 05 Jun 2025 | Legal or regulatory | Wockhardt Limited filed an updated Investor Presentation (June 2025) under Regulation 30, in continuation of its 2 June 2025 letter, and said it will also be posted on the company website. FY25 income was INR 3,033 Cr and FY25 EBITDA was INR 418 Cr, with EBITDA growth as printed on the slide and a net debt to... NSE copy |
| 05 Jun 2025 | Legal or regulatory, Management change, Credit rating | Wockhardt Limited filed its Investor Presentation (June 2025) under Regulation 30, for an investor meeting on 5 June 2025; the deck is also posted on the company website. FY25 income of INR 3,033 Cr and FY25 EBITDA of INR 418 Cr, with EBITDA growth noted year-on-year. Net Debt to Equity ratio of 0.01 as at 31 March... NSE copy |
| 29 May 2025 | Management change | Board meeting outcome filed on 29 May 2025 by Wockhardt Limited (WOCKPHARMA), which approved the audited standalone and consolidated financial results for the quarter and year ended 31 March 2025, with the statutory auditor's report (M/s. MSKC & Associates) enclosed. The Board re-appointed Mr. Akhilesh Krishna... NSE copy |
Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (10 in all). A list of what was filed, not a judgement of the company.